Brief: CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
06/01/2025 21:21
Jan 6 (Reuters) - CytomX Therapeutics Inc CTMX.O :
* CYTOMX THERAPEUTICS ANNOUNCES 2025 STRATEGIC PIPELINE
PRIORITIES
AND PROVIDES CORPORATE UPDATE
* CYTOMX THERAPEUTICS INC - INITIAL PHASE 1A DATA FOR
CX-2051
EXPECTED IN H1 2025
* CYTOMX THERAPEUTICS INC -REVISED FOCUS AND ASSOCIATED COST
AND
HEADCOUNT REDUCTIONS EXPECTED TO EXTEND CASH RUNWAY INTO Q2 OF
2026
* CYTOMX THERAPEUTICS INC -CYTOMX WILL REDUCE ORGANIZATIONAL
HEADCOUNT BY APPROXIMATELY 40 PERCENT
Source text: ID:nGNX7P8gjD
Further company coverage: CTMX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CytomX Therapeutics
See all newsCytomX Q2 revenue misses, partly hurt by lower research activities in the Astellas collaboration
CytomX Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Cytomx Therapeutics Announces Appointment Of Charles Fuchs, M.D., M.P.H., To The Board Of Directors
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway